BRCA1 and fallopian tube carcinoma: PDX TM00089 is derived from a patient with a germline pathogenic v757fs*BRCA1 mutation (truncation) who had received prior cisplatin/taxol therapy for a fallopian tube carcinoma ([31]; Mouse Models of Human Cancer Database, Jackson Research Labs).